<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12242">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504426</url>
  </required_header>
  <id_info>
    <org_study_id>249-06-002OD</org_study_id>
    <nct_id>NCT00504426</nct_id>
  </id_info>
  <brief_title>Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis</brief_title>
  <official_title>Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily
      inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to
      osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain (Subjective Symptom)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of pain measured by 100 mm visual analogue scale (VAS) at week4 from baseline.
Regarding VAS (dotted onto a 100 mm line), 0 mm means &quot;No Pain&quot; and 100 mm means &quot;Worst Pain Imaginable&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement Rate of Pain (Doctor's Judgment)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants qualified for improvement of pain by doctor's judgement.
Qualification: stopped or almost stopped, alleviated, slightly alleviated, unchanged, worsend.
Improvement defind by &quot;stopped or almost stopped&quot; or &quot;alleviated&quot;.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Pain Due to Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-249</intervention_name>
    <description>1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who fulfill all of the following items

               -  Patients with primary osteoporosis

               -  Patients who have existing 1-4 vertebral fractures

               -  Patients with back pain persisting for one week or more

               -  Postmenopausal women between 46 and less than 80 years of age
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsuhisa Saito</last_name>
    <role>Study Director</role>
    <affiliation>Division of New Product Evaluation and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 24, 2013</lastchanged_date>
  <firstreceived_date>July 16, 2007</firstreceived_date>
  <firstreceived_results_date>July 1, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo of OPC-249/vial</description>
        </group>
        <group group_id="P2">
          <title>OPC-249 (30IU)</title>
          <description>30 IU of OPC-249/vial</description>
        </group>
        <group group_id="P3">
          <title>OPC-249 (60IU)</title>
          <description>60 IU of OPC-249/vial</description>
        </group>
        <group group_id="P4">
          <title>OPC-249 (120IU)</title>
          <description>120 IU of OPC-249/vial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo of OPC-249/vial</description>
        </group>
        <group group_id="B2">
          <title>OPC-249 (30IU)</title>
          <description>30 IU of OPC-249/vial</description>
        </group>
        <group group_id="B3">
          <title>OPC-249 (60IU)</title>
          <description>60 IU of OPC-249/vial</description>
        </group>
        <group group_id="B4">
          <title>OPC-249 (120IU)</title>
          <description>120 IU of OPC-249/vial</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="22"/>
                <measurement group_id="B4" value="24"/>
                <measurement group_id="B5" value="101"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="2"/>
                <measurement group_id="B5" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="22"/>
                <measurement group_id="B5" value="91"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="71.9" spread="6.0"/>
                <measurement group_id="B2" value="73.0" spread="5.1"/>
                <measurement group_id="B3" value="73.4" spread="5.9"/>
                <measurement group_id="B4" value="72.3" spread="5.9"/>
                <measurement group_id="B5" value="72.6" spread="5.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="22"/>
                <measurement group_id="B4" value="24"/>
                <measurement group_id="B5" value="101"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Japan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="22"/>
                <measurement group_id="B4" value="24"/>
                <measurement group_id="B5" value="101"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain (Subjective Symptom)</title>
        <description>Change of pain measured by 100 mm visual analogue scale (VAS) at week4 from baseline.
Regarding VAS (dotted onto a 100 mm line), 0 mm means &quot;No Pain&quot; and 100 mm means &quot;Worst Pain Imaginable&quot;.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo of OPC-249/vial</description>
          </group>
          <group group_id="O2">
            <title>OPC-249 (30IU)</title>
            <description>30 IU of OPC-249 /vial</description>
          </group>
          <group group_id="O3">
            <title>OPC-249 (60IU)</title>
            <description>60 IU of OPC-249 /vial</description>
          </group>
          <group group_id="O4">
            <title>OPC-249 (120IU)</title>
            <description>120 IU of OPC-249 /vial</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain (Subjective Symptom)</title>
            <description>Change of pain measured by 100 mm visual analogue scale (VAS) at week4 from baseline.
Regarding VAS (dotted onto a 100 mm line), 0 mm means &quot;No Pain&quot; and 100 mm means &quot;Worst Pain Imaginable&quot;.</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-37.8" spread="28.7"/>
                  <measurement group_id="O2" value="-24.5" spread="27.3"/>
                  <measurement group_id="O3" value="-40.5" spread="26.2"/>
                  <measurement group_id="O4" value="-29.0" spread="23.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement Rate of Pain (Doctor's Judgment)</title>
        <description>Percentage of participants qualified for improvement of pain by doctor's judgement.
Qualification: stopped or almost stopped, alleviated, slightly alleviated, unchanged, worsend.
Improvement defind by &quot;stopped or almost stopped&quot; or &quot;alleviated&quot;.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo of OPC-249/vial</description>
          </group>
          <group group_id="O2">
            <title>OPC-249 (30IU)</title>
            <description>30 IU of OPC-249/vial</description>
          </group>
          <group group_id="O3">
            <title>OPC-249 (60IU)</title>
            <description>60 IU of OPC-249/vial</description>
          </group>
          <group group_id="O4">
            <title>OPC-249 (120IU)</title>
            <description>120 IU of OPC-249/vial</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Improvement Rate of Pain (Doctor's Judgment)</title>
            <description>Percentage of participants qualified for improvement of pain by doctor's judgement.
Qualification: stopped or almost stopped, alleviated, slightly alleviated, unchanged, worsend.
Improvement defind by &quot;stopped or almost stopped&quot; or &quot;alleviated&quot;.</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69.0" lower_limit="49.2" upper_limit="84.7"/>
                  <measurement group_id="O2" value="59.1" lower_limit="36.4" upper_limit="79.3"/>
                  <measurement group_id="O3" value="77.8" lower_limit="52.4" upper_limit="93.6"/>
                  <measurement group_id="O4" value="66.7" lower_limit="44.7" upper_limit="84.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo of OPC-249/vial</description>
        </group>
        <group group_id="E2">
          <title>OPC-249 (30IU)</title>
          <description>30 IU of OPC-249/vial</description>
        </group>
        <group group_id="E3">
          <title>OPC-249 (60IU)</title>
          <description>60 IU of OPC-249/vial</description>
        </group>
        <group group_id="E4">
          <title>OPC-249 (120IU)</title>
          <description>120 IU of OPC-249/vial</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Disorder gastrointestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Surfactant protein increase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood pressure rise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Limbs pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>IMAOKA, Kyoji, Operatin Officer, Gemeral Manager</name_or_title>
      <organization>Headwuarters of New Product Evaluation and Development, Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>+81-3-6361-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
